S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:AVDL

Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News

$7.31
+1.00 (+15.85%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.95
$7.63
50-Day Range
$2.20
$6.31
52-Week Range
$1.05
$11.59
Volume
1.71 million shs
Average Volume
2.01 million shs
Market Capitalization
$431.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.17

Avadel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
25.4% Upside
$9.17 Price Target
Short Interest
Healthy
13.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.51mentions of Avadel Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$155,400 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.33) to ($0.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Medical Sector

74th out of 1,098 stocks

Pharmaceutical Preparations Industry

24th out of 536 stocks

AVDL stock logo

About Avadel Pharmaceuticals (NASDAQ:AVDL) Stock

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals Stock Performance

Shares of AVDL traded up $1.09 during mid-day trading on Tuesday, hitting $7.40. 48,993 shares of the company's stock were exchanged, compared to its average volume of 806,016. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 2.11. Avadel Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $11.59. The business's 50 day moving average is $3.54 and its two-hundred day moving average is $5.17. The firm has a market capitalization of $436.90 million, a P/E ratio of -4.47 and a beta of 1.51.

Avadel Pharmaceuticals (NASDAQ:AVDL - Get Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.01). On average, equities analysts expect that Avadel Pharmaceuticals will post -1.33 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on AVDL. Oppenheimer dropped their price target on shares of Avadel Pharmaceuticals to $13.00 in a research note on Friday, May 27th. SVB Leerink decreased their price objective on shares of Avadel Pharmaceuticals from $18.00 to $6.00 and set an "outperform" rating for the company in a research note on Friday, May 27th. Stifel Nicolaus raised their price objective on Avadel Pharmaceuticals from $2.00 to $5.00 in a report on Tuesday, July 19th. HC Wainwright reissued a "buy" rating and issued a $13.00 target price on shares of Avadel Pharmaceuticals in a report on Friday, July 1st. Finally, Needham & Company LLC dropped their price target on Avadel Pharmaceuticals from $14.00 to $6.00 and set a "buy" rating on the stock in a research note on Tuesday, May 31st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $9.17.

Insider Transactions at Avadel Pharmaceuticals

In other news, CFO Thomas S. Mchugh acquired 50,000 shares of the stock in a transaction that occurred on Friday, May 27th. The shares were purchased at an average cost of $2.14 per share, for a total transaction of $107,000.00. Following the transaction, the chief financial officer now directly owns 71,500 shares in the company, valued at approximately $153,010. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Avadel Pharmaceuticals news, Director Eric J. Ende bought 15,000 shares of the company's stock in a transaction on Tuesday, May 31st. The shares were bought at an average price of $2.16 per share, for a total transaction of $32,400.00. Following the transaction, the director now owns 114,900 shares of the company's stock, valued at approximately $248,184. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Thomas S. Mchugh purchased 50,000 shares of Avadel Pharmaceuticals stock in a transaction dated Friday, May 27th. The stock was acquired at an average cost of $2.14 per share, with a total value of $107,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 71,500 shares in the company, valued at $153,010. The disclosure for this purchase can be found here. Insiders purchased 75,000 shares of company stock worth $155,400 over the last 90 days. 3.20% of the stock is currently owned by insiders.

Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Stock News Headlines

Avadel Pharmaceuticals Provides Corporate Update
Why Avadel Pharmaceuticals Stock Is Skyrocketing Today
See More Headlines
Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Company Calendar

Last Earnings
11/08/2021
Today
8/09/2022
Next Earnings (Confirmed)
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVDL
Employees
66
Year Founded
2015

Price Target and Rating

Average Stock Price Forecast
$9.17
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+25.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-77,330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$22.33 million
Book Value
$1.33 per share

Miscellaneous

Free Float
57,149,000
Market Cap
$431.57 million
Optionable
Optionable
Beta
1.51

Social Links


Key Executives

  • Mr. Gregory J. Divis Jr. (Age 55)
    CEO & Director
    Comp: $862.59k
  • Mr. Thomas S. McHugh (Age 57)
    Sr. VP & CFO
    Comp: $550k
  • Mr. Richard Kim (Age 53)
    Chief Commercial Officer
    Comp: $596.3k
  • Mr. Jerad G. Seurer
    Gen. Counsel & Company Sec.
  • Mr. Gregory J. Davis (Age 57)
    VP of Corp. and Bus. Devel.
  • Mr. Mark W. Elrod
    VP of Sales
  • Ms. Angie Woods
    VP of People & Culture
  • Mr. Christian Kalita Pharm.D
    Chief Pharmacist and Director of Quality Assurance & Regulatory Affairs
  • Mr. Steven G. Sullivan (Age 57)
    VP of Sales & Marketing and Head of Commercial Operations
  • Dr. Jordan S. Dubow M.D. (Age 44)
    Consultant













AVDL Stock - Frequently Asked Questions

Should I buy or sell Avadel Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVDL shares.
View AVDL analyst ratings
or view top-rated stocks.

What is Avadel Pharmaceuticals' stock price forecast for 2022?

5 equities research analysts have issued 12 month target prices for Avadel Pharmaceuticals' stock. Their AVDL share price forecasts range from $5.00 to $13.00. On average, they predict the company's stock price to reach $9.17 in the next twelve months. This suggests a possible upside of 29.7% from the stock's current price.
View analysts price targets for AVDL
or view top-rated stocks among Wall Street analysts.

How has Avadel Pharmaceuticals' stock price performed in 2022?

Avadel Pharmaceuticals' stock was trading at $8.08 at the beginning of 2022. Since then, AVDL stock has decreased by 12.5% and is now trading at $7.07.
View the best growth stocks for 2022 here
.

When is Avadel Pharmaceuticals' next earnings date?

Avadel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our AVDL earnings forecast
.

How were Avadel Pharmaceuticals' earnings last quarter?

Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.38) EPS for the quarter, hitting analysts' consensus estimates of ($0.38). During the same period in the previous year, the business posted ($0.20) EPS.

What other stocks do shareholders of Avadel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY).

What is Avadel Pharmaceuticals' stock symbol?

Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."

Who are Avadel Pharmaceuticals' major shareholders?

Avadel Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wealth Effects LLC (4.38%), Modera Wealth Management LLC (0.72%), CIBC Private Wealth Group LLC (0.28%), Edge Wealth Management LLC (0.26%), Investors Asset Management of Georgia Inc. GA ADV (0.24%) and Schulhoff & Co. Inc. (0.16%). Insiders that own company stock include Eric J Ende, Geoffrey Michael Glass, Greg J Divis, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish, Sandra L Hatten and Thomas S Mchugh.
View institutional ownership trends
.

How do I buy shares of Avadel Pharmaceuticals?

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avadel Pharmaceuticals' stock price today?

One share of AVDL stock can currently be purchased for approximately $7.07.

How much money does Avadel Pharmaceuticals make?

Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $417.41 million and generates $22.33 million in revenue each year. The company earns $-77,330,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.

How many employees does Avadel Pharmaceuticals have?

Avadel Pharmaceuticals employs 66 workers across the globe.

When was Avadel Pharmaceuticals founded?

Avadel Pharmaceuticals was founded in 2015.

How can I contact Avadel Pharmaceuticals?

Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 485-1200, via email at investors@avadel.com, or via fax at 353-1526-1077.

This page (NASDAQ:AVDL) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.